middle.news
How Will Prescient’s PTX-100 Transform Treatment for Rare CTCL?
9:17am on Monday 15th of December, 2025 AEDT
•
Healthcare
Read Story
How Will Prescient’s PTX-100 Transform Treatment for Rare CTCL?
9:17am on Monday 15th of December, 2025 AEDT
Key Points
European CTIS approval granted for PTX-100 trial in relapsed/refractory CTCL
Trial sites in Italy now activated for patient recruitment
PTX-100 is a first-in-class GGT-1 inhibitor targeting cancer growth pathways
Phase 2a study aims to enroll up to 40 patients with high unmet medical need
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE